Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Alumis Inc. Common StockNASDAQ: ALMS

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue declines year over year

Q2 FY2026 revenue of $1.66M fell 37.7% year over year, ahead of the -63.1% change in trailing-twelve-month revenue. Sequentially, it fell 4.5% from the prior quarter.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 8 analysts of $7.18M (-70.2%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.66M-4.5% QoQ
Last fiscal yearDec 2025
$24.05M— YoY
LTMJun 2026
$7.4M-63.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.7%-8.0%+29.6 pp
1 year—-70.2%—
3-year CAGR—+86.3%—
5-year CAGR+105.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
24.05M USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -63.1% is the 4th highest of 6, against a peer median of -52.9%.
ALMS Competitors
Revenue for ALMS and competitors
Company Period LTM YoY 3-year CAGR
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$299.77M USD+47.6%+34.8%
ANABAnaptysBio, Inc.LTM Mar 2026$232.39M USD+107.7%+183.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$8.37M USD-52.9%-35.9%
ALMSAlumis Inc. Common StockLTM Jun 2026$7.4M USD-63.1%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$59K USD-86.6%-85.2%
IFRXInflaRx N.V.LTM Mar 2026€29.33K EUR-77.4%—
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€0 EUR——
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD——
TLSATiziana Life Sciences LtdFY2025$0 USD——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD——
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding ALMS) —-52.9%-0.6%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00024.05M
Cost of Revenue250K03.15M3.5M
Gross Profit(250K)0(3.15M)20.55M
Gross Margin———85.5%
Research & Development101.05M137.68M265.55M386M
Selling, General & Admin12.55M20.5M35.2M91.86M
Operating Expenses113.6M158.17M297.6M447.76M
Depreciation & Amortization250K1.28M3.15M3.5M
EBITDA(111.68M)(153.71M)(291.08M)(248.39M)
EBITDA Margin———-1032.8%
Operating Income(113.85M)(158.17M)(300.75M)(427.2M)
Operating Margin———-1776.3%
Interest Income1.99M3.37M12.02M14.18M
Interest Expense0000
Other Income / Expenses1.92M3.18M6.52M175.32M
Income Before Tax(111.93M)(154.99M)(294.23M)(251.89M)
Pre-Tax Margin———-1047.3%
Income Tax Expense000(8.56M)
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Net Margin———-1011.7%
EPS (Basic)(14.93)(2.99)(10.38)(2.32)
EPS (Diluted)(14.93)(2.99)(10.38)(2.32)
Weighted Avg Shares7.5M51.84M28.34M850.3M
Weighted Avg Shares (Diluted)7.5M51.84M28.34M850.3M

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.